The stock has been trading at $0.20 per share and has settled in a tight trading range, establishing a safe entry point for new investors. I am confident that OncoSec Medical (ONCS) is not going to remain a penny stock for long.
Interestingly, with numerous immunotherapeutic companies bringing in new technologies, successful treatments and approvals from FDA, I strongly believe that stock prices of all these biotech companies are on the verge of jumping. Celgene Corporation (NASDAQ:CELG), on February 8th, 2013, received approval from the FDA, for its new immunomodulatory drug, pomalidomide, designed to treat multiple myeloma. This is expected to boost the company’s revenues by 66% in 2013, which were around $4 billion in 2012.
Onyx Pharmaceutical’s (NASDAQ:ONXX) multiple myeloma drug, Kyprolis, which was granted FDA approval earlier in 2012, is also doing well. Vical Incorporated (NASDAQ:VICL) is developing an immunotherapy drug, Allovectin, to treat melanoma in the late stages. Currently, it is under clinical reviewing process in phase three. This treatment is targeted at killing cancer cells through an allogeneic anti-tumor response.
While I believe the market is strong and will continue to grow, I do believe OncoSec’s technology offers substantially more marketability than the rest and it should, at the least, be able to capture a leadership share in the market.
Merkel cell carcinoma is a rare but deadly disease, which has a 40% mortality rate. OncoSec Medical is conducting “OMS ElectroImmunotherapy—ImmunoPulse” to deliver DNA IL-12 in patients with local and metastatic Merkel cell carcinoma (OMS-I110) in cooperation with the University of Washington. The therapy is in its second phase trials.
Melanoma, with around 70,000 cases being registered every year, is another type of a skin cancer. To treat this, OncoSec Medical is conducting “ImmunoPulse” to deliver DNA IL-12 in patients with late-stage metastatic melanoma (OMS-I100) along with the University of California, San Francisco. This therapy is in its second trial phase. Around 53% of patients suffering from this disease, have given a positive response to this treatment. This trial will enroll approximately 25 patients with advanced-stage, cutaneous, in-transit malignant melanoma.
Cutaneous T-cell lymphomais anothertype of blood cancer that is difficult to treat and has not responded well to other regular therapies in the long run. Again, “ImmunoPulse therapy” has proven to be the best way to treat this disease and provide relief in the long run. This therapy is also in its second phase. This phase involves treating 27 patients suffering from this disease.